Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab in Autoimmune Disease
NCT06413511Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Jun 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label, single-arm trial of belantamab mafodotin in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and antiphospholipid syndrome (APS), sponsored by GSK. Primary endpoints: Number of participants with adverse events (AEs) and serious adverse events (SAEs), Number of participants with clinically important findings in vital signs and 6 more. Planned start Jun 2024; status: withdrawn.
02
Drugs
belantamab mafodotin
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT06413511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413511.